When does the Orkambi (lumacaftor/ivacaftor) EU patent expire?
I don’t have any Orkambi (lumacaftor/ivacaftor) EU patent-expiration dates in the provided information, so I can’t state an accurate expiry date.
What usually controls Orkambi’s EU exclusivity timing (patents vs. other protections)?
Even when a “patent expiration” date is known, market exclusivity in the EU can also be affected by:
- the term and coverage of the relevant patents (drug substance, formulations, combinations, or specific claims)
- any supplementary protection certificates (SPCs), which can extend exclusivity based on marketing authorization timing
- patent-related settlements or pending litigation that can delay generic/biosimilar entry
- data/exclusivity periods attached to the original marketing authorization (separate from patents)
How to find the exact Orkambi EU patent expiry you need
To get the correct date, you typically need to identify the exact patent family and protection type relevant to Orkambi in the EU (and then check whether an SPC applies). The fastest path is usually:
1) find the Orkambi EU marketing authorization details, including date and MA holder
2) map that to the relevant Orkambi patent family in Europe
3) check whether an SPC was granted and its expiry
4) confirm whether any later patent(s) are still in force for key claims
What I need from you to give a precise expiry date
If you share any one of the following, I can help pin down the right expiration window:
- the specific EU country/territory you mean (e.g., “EU-wide” vs. a specific member state)
- the patent number or a link to the patent record you’re looking at
- whether you care about “patent expiry” specifically or “regulatory exclusivity/SPC expiry”
- the marketing authorization holder you’re using in your search
Sources
No sources were provided in your message, and I can’t verify Orkambi EU patent-expiration dates without them.